Targeted gene delivery to the brain using CDX-modified chitosan nanoparticles.

Area of Science:

• Biotechnology
• Nanomedicine
• Neuroscience

Background:

• The blood-brain barrier restricts molecule transport to the brain.
• Gene therapy shows potential for nervous system disorders but requires efficient delivery carriers.
• Developing effective biocarriers for brain gene delivery remains a significant challenge.

Purpose of the Study:

• To develop and characterize chitosan (CS) nanoparticles modified with CDX peptide for delivering pEGFP-N1 plasmid into the brain parenchyma.
• To evaluate the efficiency of CS-PEG-CDX nanoparticles in delivering genetic material to the central nervous system (CNS).

Main Methods:

• Chitosan nanoparticles (CS-PEG-CDX) were synthesized using a bifunctional polyethylene glycol (PEG) linker and the ionic gelation method.
• Nanoparticles and their complexes with pEGFP-N1 plasmid (CS-PEG-CDX/pEGFP) were characterized using DLS, NMR, FTIR, and TEM.
• In vitro cell internalization was assessed using a rat C6 glioma cell line.
• In vivo biodistribution and brain localization were studied in mice via intraperitoneal injection using imaging techniques.

Main Results:

• CS-PEG-CDX/pEGFP nanoparticles demonstrated dose-dependent uptake by glioma cells.
• In vivo imaging confirmed successful entry of nanoparticles into the brain parenchyma, evidenced by green fluorescent protein (GFP) expression.
• Significant accumulation of nanoparticles was also observed in organs such as the spleen, liver, heart, and kidneys.

Conclusions:

• Chitosan nanoparticles modified with CDX peptide (CS-PEG-CDX) show potential as safe and effective nanocarriers for brain gene delivery.
• This approach offers a promising strategy for therapeutic interventions targeting the central nervous system.
• Further research is warranted to optimize targeting and minimize off-target accumulation.